CELLULARLINE SPA (CELL.MI) Stock Fundamental Analysis
Europe - Euronext Milan - BIT:CELL - IT0005244618 - Common Stock
2.565 EUR
+0.06 (+2.6%)
Overall CELL gets a fundamental rating of 5 out of 10. We evaluated CELL against 33 industry peers in the Technology Hardware, Storage & Peripherals industry. While CELL has a great health rating, its profitability is only average at the moment. CELL is valued quite cheap, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year CELL was profitable.
CELL had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: CELL reported negative net income in multiple years.
In the past 5 years CELL always reported a positive cash flow from operatings.
1.2 Ratios
CELL has a Return On Assets of 2.60%. This is comparable to the rest of the industry: CELL outperforms 54.55% of its industry peers.
CELL's Return On Equity of 4.27% is fine compared to the rest of the industry. CELL outperforms 63.64% of its industry peers.
CELL's Return On Invested Capital of 4.42% is in line compared to the rest of the industry. CELL outperforms 48.48% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.6% | ||
| ROE | 4.27% | ||
| ROIC | 4.42% |
ROA(3y)-10.28%
ROA(5y)-5.5%
ROE(3y)-16.94%
ROE(5y)-9.21%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a Profit Margin value of 3.44%, CELL perfoms like the industry average, outperforming 51.52% of the companies in the same industry.
CELL's Profit Margin has declined in the last couple of years.
CELL's Operating Margin of 4.91% is in line compared to the rest of the industry. CELL outperforms 57.58% of its industry peers.
In the last couple of years the Operating Margin of CELL has declined.
Looking at the Gross Margin, with a value of 40.07%, CELL is in the better half of the industry, outperforming 66.67% of the companies in the same industry.
In the last couple of years the Gross Margin of CELL has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 4.91% | ||
| PM (TTM) | 3.44% | ||
| GM | 40.07% |
OM growth 3Y35.04%
OM growth 5Y-19.56%
PM growth 3YN/A
PM growth 5Y-23.32%
GM growth 3Y-2.78%
GM growth 5Y-2.73%
2. Health
2.1 Basic Checks
CELL has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
CELL has less shares outstanding than it did 1 year ago.
CELL has less shares outstanding than it did 5 years ago.
The debt/assets ratio for CELL has been reduced compared to a year ago.
2.2 Solvency
CELL has an Altman-Z score of 2.34. This is not the best score and indicates that CELL is in the grey zone with still only limited risk for bankruptcy at the moment.
With a decent Altman-Z score value of 2.34, CELL is doing good in the industry, outperforming 60.61% of the companies in the same industry.
The Debt to FCF ratio of CELL is 2.46, which is a good value as it means it would take CELL, 2.46 years of fcf income to pay off all of its debts.
CELL has a better Debt to FCF ratio (2.46) than 72.73% of its industry peers.
CELL has a Debt/Equity ratio of 0.13. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of CELL (0.13) is better than 81.82% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.13 | ||
| Debt/FCF | 2.46 | ||
| Altman-Z | 2.34 |
ROIC/WACC0.5
WACC8.78%
2.3 Liquidity
A Current Ratio of 2.12 indicates that CELL has no problem at all paying its short term obligations.
With a decent Current ratio value of 2.12, CELL is doing good in the industry, outperforming 63.64% of the companies in the same industry.
CELL has a Quick Ratio of 1.33. This is a normal value and indicates that CELL is financially healthy and should not expect problems in meeting its short term obligations.
CELL's Quick ratio of 1.33 is fine compared to the rest of the industry. CELL outperforms 66.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.12 | ||
| Quick Ratio | 1.33 |
3. Growth
3.1 Past
CELL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 60.78%, which is quite impressive.
The earnings per share for CELL have been decreasing by -20.43% on average. This is quite bad
CELL shows a small growth in Revenue. In the last year, the Revenue has grown by 3.54%.
Measured over the past years, CELL shows a small growth in Revenue. The Revenue has been growing by 3.18% on average per year.
EPS 1Y (TTM)60.78%
EPS 3YN/A
EPS 5Y-20.43%
EPS Q2Q%-4.76%
Revenue 1Y (TTM)3.54%
Revenue growth 3Y14.1%
Revenue growth 5Y3.18%
Sales Q2Q%-2.91%
3.2 Future
The Earnings Per Share is expected to grow by 2.47% on average over the next years.
CELL is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -0.60% yearly.
EPS Next Y-12.5%
EPS Next 2Y2.47%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-5.69%
Revenue Next 2Y-0.6%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 9.87, which indicates a very decent valuation of CELL.
Compared to the rest of the industry, the Price/Earnings ratio of CELL indicates a rather cheap valuation: CELL is cheaper than 87.88% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of CELL to the average of the S&P500 Index (26.15), we can say CELL is valued rather cheaply.
With a Price/Forward Earnings ratio of 5.99, the valuation of CELL can be described as very cheap.
Based on the Price/Forward Earnings ratio, CELL is valued cheaper than 93.94% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of CELL to the average of the S&P500 Index (36.22), we can say CELL is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.87 | ||
| Fwd PE | 5.99 |
4.2 Price Multiples
93.94% of the companies in the same industry are more expensive than CELL, based on the Enterprise Value to EBITDA ratio.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of CELL indicates a rather cheap valuation: CELL is cheaper than 96.97% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 3.76 | ||
| EV/EBITDA | 2.99 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.47%
EPS Next 3YN/A
5. Dividend
5.1 Amount
CELL has a Yearly Dividend Yield of 3.77%.
Compared to an average industry Dividend Yield of 2.16, CELL pays a better dividend. On top of this CELL pays more dividend than 90.91% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 2.32, CELL pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.77% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
CELL pays out 34.37% of its income as dividend. This is a sustainable payout ratio.
DP34.37%
EPS Next 2Y2.47%
EPS Next 3YN/A
BIT:CELL (12/1/2025, 5:29:46 PM)
2.565
+0.06 (+2.6%)
Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupTechnology Hardware & Equipment
GICS IndustryTechnology Hardware, Storage & Peripherals
Earnings (Last)
Earnings (Next)
Inst Owners5.79%
Inst Owner ChangeN/A
Ins Owners19.57%
Ins Owner ChangeN/A
Market Cap56.10M
Revenue(TTM)164.26M
Net Income(TTM)5.65M
Analysts82.86
Price Target4.18 (62.96%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.77% |
Yearly Dividend0.08
Dividend Growth(5Y)N/A
DP34.37%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-12.77%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-28.57%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-11.02%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.87 | ||
| Fwd PE | 5.99 | ||
| P/S | 0.34 | ||
| P/FCF | 3.76 | ||
| P/OCF | 2.76 | ||
| P/B | 0.42 | ||
| P/tB | 1.03 | ||
| EV/EBITDA | 2.99 |
EPS(TTM)0.26
EY10.14%
EPS(NY)0.43
Fwd EY16.7%
FCF(TTM)0.68
FCFY26.59%
OCF(TTM)0.93
OCFY36.19%
SpS7.51
BVpS6.05
TBVpS2.49
PEG (NY)N/A
PEG (5Y)N/A
Graham Number5.95
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.6% | ||
| ROE | 4.27% | ||
| ROCE | 5.04% | ||
| ROIC | 4.42% | ||
| ROICexc | 5.33% | ||
| ROICexgc | 12.93% | ||
| OM | 4.91% | ||
| PM (TTM) | 3.44% | ||
| GM | 40.07% | ||
| FCFM | 9.08% |
ROA(3y)-10.28%
ROA(5y)-5.5%
ROE(3y)-16.94%
ROE(5y)-9.21%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y46.34%
ROICexgc growth 5Y-17.53%
ROICexc growth 3Y77.77%
ROICexc growth 5Y-8.95%
OM growth 3Y35.04%
OM growth 5Y-19.56%
PM growth 3YN/A
PM growth 5Y-23.32%
GM growth 3Y-2.78%
GM growth 5Y-2.73%
F-Score4
Asset Turnover0.76
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.13 | ||
| Debt/FCF | 2.46 | ||
| Debt/EBITDA | 0.81 | ||
| Cap/Depr | 39.19% | ||
| Cap/Sales | 3.28% | ||
| Interest Coverage | 2.77 | ||
| Cash Conversion | 93.13% | ||
| Profit Quality | 264.18% | ||
| Current Ratio | 2.12 | ||
| Quick Ratio | 1.33 | ||
| Altman-Z | 2.34 |
F-Score4
WACC8.78%
ROIC/WACC0.5
Cap/Depr(3y)26.8%
Cap/Depr(5y)35.01%
Cap/Sales(3y)3.22%
Cap/Sales(5y)4.78%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)60.78%
EPS 3YN/A
EPS 5Y-20.43%
EPS Q2Q%-4.76%
EPS Next Y-12.5%
EPS Next 2Y2.47%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)3.54%
Revenue growth 3Y14.1%
Revenue growth 5Y3.18%
Sales Q2Q%-2.91%
Revenue Next Year-5.69%
Revenue Next 2Y-0.6%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y59.25%
EBIT growth 3Y54.08%
EBIT growth 5Y-17%
EBIT Next Year28.5%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y1050.19%
FCF growth 3Y4.84%
FCF growth 5Y6.28%
OCF growth 1Y730.91%
OCF growth 3Y4.12%
OCF growth 5Y1.2%
CELLULARLINE SPA / CELL.MI FAQ
What is the ChartMill fundamental rating of CELLULARLINE SPA (CELL.MI) stock?
ChartMill assigns a fundamental rating of 5 / 10 to CELL.MI.
What is the valuation status of CELLULARLINE SPA (CELL.MI) stock?
ChartMill assigns a valuation rating of 7 / 10 to CELLULARLINE SPA (CELL.MI). This can be considered as Undervalued.
What is the profitability of CELL stock?
CELLULARLINE SPA (CELL.MI) has a profitability rating of 4 / 10.
How financially healthy is CELLULARLINE SPA?
The financial health rating of CELLULARLINE SPA (CELL.MI) is 7 / 10.
What is the expected EPS growth for CELLULARLINE SPA (CELL.MI) stock?
The Earnings per Share (EPS) of CELLULARLINE SPA (CELL.MI) is expected to decline by -12.5% in the next year.